Featured

Trump: Iran asked me to be Supreme Leader, but I said no thanks

Trump’s “Iran asked me to be Supreme Leader” joke at an NRCC fundraiser uses a real, deadly leadership crisis in Iran to normalize assassination-as-policy and blur what’s confirmed about the war and succession.

Mar 26, 2026

Featured

‘Men need to be perp-walked’ after Epstein files release, Massie tells BBC

A GOP lawmaker says the Epstein document releases are still falling short—because redactions and withheld material may be blocking accountability and survivor-centered justice.

Mar 25, 2026

Buried.News

The stories buried under the noise

Primary focus

Trump fires Kristi Noem as Homeland Security Secretary

A Cabinet secretary was forced out amid contracting and oversight scrutiny, signaling that executive control—not transparent accountability—can dictate leadership of the agency driving mass detention and deportation.

Mar 5, 2026

Featured

The Trump gold coin is not normal : Consider This from NPR

A federal design panel OK’d a Trump portrait for a commemorative gold coin, but the key question is whether Treasury can legally bypass long-standing limits meant to keep living politicians off U.S. money.

Mar 23, 2026

Featured

White House Confronted Over Huge Bets Made Minutes Before Trump’s Big War Move

A $580 million burst of oil-futures selling minutes before Trump’s Iran “talks” post raises a basic public-interest question: did anyone trade on advance knowledge of a market-moving national security decision?

Mar 24, 2026

Japan approves stem-cell treatment for Parkinson

Japan’s health ministry is fast-tracking iPS cell therapies under conditional licenses that move commercial medicine to market on smaller-than-usual trial evidence.

General

Mar 6, 2026

Sources

https://www.france24.com/en/live-news/20260306-japan-approves-stem-cell-treatment-for-parkinson-s-in-world-first

Summary

Japan’s health ministry approved conditional, time-limited manufacture and sale of iPS cell-based therapies for Parkinson’s disease and heart repair. The decision uses a fast-track approval system that relies on efficacy and safety assessments drawn from fewer patients than ordinary clinical trials. The approvals could place the first commercially available iPS cell products on the market as early as this summer, accelerating patient access while locking in a precedent for provisional licensing in regenerative medicine.

Detail

Sumitomo Pharma announced it received approval to manufacture and sell Amchepry, a Parkinson’s disease treatment that transplants stem cells into a patient’s brain. Japan’s health ministry also approved ReHeart, heart muscle sheets developed by startup Cuorips, which media reports said can help form new blood vessels and restore heart function.

Reports citing the health ministry said both products could reach the market and patients as early as this summer, described as the world’s first commercially available medical products using induced pluripotent stem (iPS) cells.

Sumitomo Pharma said Amchepry received “conditional and time-limited approval” under a system designed to speed patient access. The Asahi newspaper described this as a provisional license issued after safety and efficacy were judged using data from fewer patients than typical drug trials.

A Kyoto University-led study followed seven Parkinson’s patients for two years after implantation of five million or 10 million iPS-derived dopamine-cell precursors on both sides of the brain, reporting no major adverse effects and symptom improvements in four patients.